Role of lipocalin-2 in the development and progression of liver diseases
10.3969/j.issn.1001-5256.2022.09.044
- VernacularTitle:脂质运载蛋白2在肝脏疾病发生发展中的作用
- Author:
Zhengguang LIAO
1
;
Shihui WEI
1
;
Danyu DU
1
;
Li SUN
1
;
Shengtao YUAN
1
Author Information
1. Jiangsu Key Laboratory for New Drug Screening, Institute of Pharmaceutical Research, China Pharmaceutical University, Nanjing 210009, China
- Publication Type:Reviews
- Keywords:
Liver Diseases;
Lipocalin-2;
Pathologic Processes
- From:
Journal of Clinical Hepatology
2022;38(9):2177-2181
- CountryChina
- Language:Chinese
-
Abstract:
Lipocalin-2 (LCN2) is a secreted glycoprotein originally purified from mouse kidney cells infected with simian virus 40 and plays a key role in the control of cellular homeostasis during inflammation and the response to cellular stress or injury, and it is considered a potential biomarker for rheumatic diseases, cancer, liver diseases, and inflammatory diseases. Studies have shown that LCN2 is expressed in hepatic parenchymal and nonparenchymal cells and is secreted into the bloodstream, and it is closely associated with the development and progression of acute liver injury, liver cirrhosis, viral hepatitis, alcoholic liver disease, nonalcoholic fatty liver disease, and hepatocellular carcinoma. This article summarizes the animal experiments and clinical studies on the association of LCN2 with the pathogenesis of liver diseases, in order to provide new ideas and therapeutic targets for the prevention and treatment of liver diseases.
